RxDoctor Payments Data

Douglas Moss, MD

Obstetrics & Gynecology · New York, NYNPI 1114016631

Payments from drug & device makers

$3,811in general payments, 2019–2025

Across 214 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Celularity Inc.$336
  • Evofem Biosciences, Inc.$316
  • AbbVie$272
  • Exact Sciences$271
  • Amgen$253
  • Millicent US Inc$227
  • plus $2K from 27 others

What the payments were for

  • Speaking & faculty fees$3008%
  • Food & beverage$3,48191%
  • Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,811 in reported general payments places this provider in the 90th percentile of 2,673 obstetrics & gynecology providers in New York.

See all obstetrics & gynecology providers in New York

Medicare billing

Part B allowed, 2024
$25,495
Medicare patients
147
Services billed
357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab14$24,078
MyrbetriqMirabegron21$11,942
Estradiol176$10,139
EstringEstradiol12$6,266
YuvafemEstradiol29$5,032
ImvexxyEstradiol18$4,722
PremproEstrogen,con/M-Progest Acet13$3,161
ProgesteroneProgesterone, Micronized97$3,099
EstraceEstradiol11$2,721
Raloxifene Hcl18$1,724
Estradiol (Twice Weekly)Estradiol17$671
ValacyclovirValacyclovir Hcl15$438
Ibandronate Sodium19$311
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$311
Nystatin19$241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$253$24,07814 claims
Astellas Pharma US IncMyrbetriq$192$11,94221 claims
PfizerEstring, Prempro$159$9,42725 claims
Therapeuticsmd, Inc.Imvexxy$220$4,72218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,673 obstetrics & gynecology providers in New York.

Other obstetrics & gynecology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →